Is Aehr Test Systems Stock a Buy or Sell After Hedge Fund Halter Ferguson Dumped Shares Worth $20 Million?

Halter Ferguson Financial sold 627,498 shares of Aehr Test Systems in Q1, reducing its stake to 14,631 shares valued at $542,522 and cutting the position to just 0.12% of AUM from 2.8% previously. The sale was estimated at about $20.07 million, while Aehr’s shares had surged to $88.48 by April 27, up 917% year over year and briefly reaching $102.48 in April. The move reflects cautious positioning after a sharp rally tied to AI-related demand, but it is more a portfolio flow update than a major catalyst.

Analysis

The key signal is not simply that a fund sold a winner; it is that the position was reduced from a meaningful portfolio sleeve to a token residual after a vertical move, which usually tells you the seller is prioritizing liquidity and variance control over further upside capture. That matters because names that rerate on a single customer/order narrative often experience a second derivative slowdown once the marginal buyer steps away and the story has to convert into repeatable revenue. In that setup, the stock can remain “good news sensitive” but becomes vulnerable to any delay, order-size normalization, or margin disappointment.

The larger second-order effect is on the AI hardware supply chain narrative: if AEHR’s order book is being capitalized as an AI proxy while revenue is still lumpy, investors may be over-earning the duration of the AI test-and-burn cycle. Competitors and adjacent equipment vendors with more diversified customer bases could benefit from capital rotating away from the single-name momentum trade into broader semiconductor capital equipment exposure. Meanwhile, the extreme multiple leaves very little room for evidence that the recent demand spike was front-loaded rather than structural.

Near term, the main risk is a valuation reset rather than a fundamental collapse. A 10%–15% drawdown can happen quickly if the market starts questioning conversion of orders into shipments; a more durable de-rating would likely require one or two quarters of sequential revenue softness or commentary that the AI customer is non-recurring. Conversely, if management confirms repeat orders and improving gross margin, the stock can extend, but the burden of proof has risen sharply and the easiest money has likely been made.

The contrarian view is that the selloff risk may be underappreciated because momentum holders tend to crowd late into scarcity stories, especially when the float is small and short interest can amplify upside. But the more important contrarian point is that the optimal expression is probably not outright bearishness on semicap demand; it is a relative-value short in the most extended beneficiary versus a basket of more established, cash-generative equipment names.

Key Decisions for Investors

• Short AEHR on strength or via 1-2 month call spreads if implied vol is rich; thesis is multiple compression once the market demands repeatable revenue rather than one-off order headlines.
• Pair trade: short AEHR / long a diversified semicap basket over the next 4-8 weeks to isolate valuation and customer-concentration risk while limiting beta to AI hardware sentiment.
• If already long AEHR, trim into rallies and keep only a core tactical position; use a trailing stop around a 10% drawdown from recent highs because the stock’s path dependency is now unfavorable.
• Watch for the next earnings/quarterly update as the key catalyst window; if sequential revenue does not inflect, add to the short on any post-print bounce.
• Consider rotating incremental capital into better-quality AI infrastructure beneficiaries with clearer revenue visibility rather than chasing AEHR’s scarcity premium.